Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Iterum Therapeutics ( (ITRM) ) just unveiled an announcement.
On July 29, 2025, Iterum Therapeutics International Limited entered into a Commercial Manufacturing and Supply Agreement with ACS Dobfar S.p.A for the production and supply of ORLYNVAHTM bilayer tablets. This agreement, initially set for five years with a two-year renewal option, outlines ACS’s responsibilities in manufacturing and delivering the tablets and bulk drug substances as per Iterum’s requirements, ensuring compliance with quality and regulatory standards, and includes provisions for pricing, confidentiality, and liability.
The most recent analyst rating on (ITRM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.
Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics is a pharmaceutical company focused on developing and commercializing anti-infectives aimed at combating multi-drug resistant pathogens.
Average Trading Volume: 653,254
Technical Sentiment Signal: Sell
Current Market Cap: $30.84M
Learn more about ITRM stock on TipRanks’ Stock Analysis page.